Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of recombinant live attenuated mumps vaccine (F genotype)
ChiCTR2300078725Phase 2Recruiting
- Sponsor
- Hubei Provincial Center for Disease Control and Prevention
- Start
- Nov 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2 trial of mumps vaccine, live, attenuated in mumps (3 arms), sponsored by Hubei Provincial Center for Disease Control and Prevention. Primary endpoints: Serum anti-F genotype mumps virus neutralizing antibody seroconversion rate at Day 30 and Incidence of adverse reactions within 30 days after immunization. Started Nov 2023; status: recruiting.
02
Drugs
mumps vaccine, live, attenuated
03
Conditions
mumps
Beyond the preview
Go deeper on ChiCTR2300078725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300078725.